Solu Therapeutics Shares Promising Preclinical Results for STX-0712 in Leukemia at ASH

Solu Therapeutics, a biotech firm leading the development of therapies to eradicate disease-causing cells in cancer, immunology, and other fields, has reported favorable preclinical findings for STX-0712, its innovative CCR2-CyTAC™ (Cytotoxicity Targeting Chimera) for treating chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). The findings were showcased in two poster presentations during the American Society of Hematology (ASH) Annual Meeting, which took place from December 7-10, 2024, in San Diego, California.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

"The promising outcomes from our preclinical research in CMML and AML underscore the distinctive capability of our CyTAC platform to accurately target and eradicate cells that drive disease," stated Sergio Santillana, Chief Medical Officer at Solu. "The selective targeting of CCR2-positive malignant monocytes by STX-0712 in these two complex blood cancers demonstrates the platform's potential to facilitate the development of groundbreaking treatments for various cancers and other conditions. We are eager to move STX-0712 into clinical trials and to continue utilizing our platform to address other diseases with high unmet needs."

CCR2 was found to be highly expressed in over 98% of malignant monocytes in peripheral blood and in a subset of CD34+ progenitors in the bone marrow of CMML patients, whereas CD34+ progenitor healthy controls showed minimal or no CCR2 expression.

In all patient samples examined, STX-0712 efficiently depleted CD14+CCR2+ monocytes, achieving 66–91% cancer cell elimination with an average potency of 3nM.

In non-human primates (NHPs), STX-0712 showed strong dose-dependent activity, effectively depleting more than 95% of CCR2-positive monocytes.

STX-0712 displayed favorable pharmacokinetics in NHPs and was well tolerated, with no adverse effects noted.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

According to the data provided by the Synapse Database, As of December 12, 2024, there are 45 investigational drugs for the CCR2 target, including 92 indications, 48 R&D institutions involved, with related clinical trials reaching 103, and as many as 9904 patents.

STX-0712 is an antibody drug conjugate (ADC) that targets CCR2 and is being developed for the treatment of Neoplasms, Hemic and Lymphatic Diseases, and Other Diseases. The drug is currently being studied for its potential applications in Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia. STX-0712 is being developed by Solu Therapeutics, Inc., and it is currently in the preclinical phase of development.